CLINICAL_TRIALS ClinicalTrials.gov record update

XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05970302
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:02.898193+00:00
Published At: 2023-08-01T00:00:00+00:00
Record Updated At: 2023-08-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Tislelizumab", "Bevacizumab", "Oxaliplatin", "Capecitabine", "MSS/pMMR", "Metastatic Colorectal Cancer (mCRC)", "RAS-mutated", "First-Line"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-08-01"
protocolSection.identificationModule.nctId: "NCT05970302"
protocolSection.identificationModule.officialTitle: "XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study."
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.